Effect of Myristica fragrans in Pulp therapy of Primary teeth

Comparative Evaluation of Myristica fragrans efficacy as a pulpotomy medicament with Mineral trioxide aggregate and with Zinc oxide Eugenol as an obturating material in Primary teeth (for Humans).

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/05/025148

Enrollment

100

Registered

2020-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Myristica fragrans: Essential oil of Myristica fragrans used as medicament pulpotomy and as Pulpectomy obturating material. Control Intervention1: Mineral tri oxide aggregate ans compar

Eligibility

Inclusion criteria

Inclusion criteria: For Pulpotomy group: 1. No history of spontaneous or nocturnal pain 2. Absence of tenderness to percussion 3. Absence of physiologic or pathologic tooth mobility 4. No clinical evidence of pulpal inflammation or degeneration such as history of swelling or presence of sinus tract 5. Normal tooth structure 6. Restorable teeth 7. Absence of radiographic evidence of internal or external root resorption, pulpal calcification, or osseous disease (periapical or furcation radiolucency). 8. Presence of at least two-thirds of the root (no physiologic root resorption of more than one-third of the root length). 9. Patientâ??s parents/guardians who provide consent. For Pulpectomy : 1. Patients aged 4 to 9 years with no history of systemic illness. 2. Teeth with caries, diagnosed as having irreversible pulpitis. 3. Teeth which are restorable. 4. Teeth with at least two-third of intact root length.

Exclusion criteria

Exclusion criteria: For pulpotomy: 1. Hemostasis could not be achieved within 5 minutes by direct contact with a wet cotton pellet, prior to material placement. 2. The remaining radicular tissue was non-vital (with suppuration or purulence necrosis). 3. Medically compromised patient. For Pulpectomy: 1. Teeth with pre-shedding and abnormal pathologic mobility. 2. Teeth with perforation of pulpal floor. 3. Teeth with missing succedaneous tooth. 4. Presence of resorption (external or internal). 5. Presence of pulp canal calcifications. 6. Medically compromised patients

Design outcomes

Primary

Measure	Time frame
Absence of Pain, Absence of swelling, Absence of Mobility, Radiographic healing, absence of abscessTimepoint: 3 months, 6 months, 9 months and 12 months.	—

Secondary

Measure	Time frame
Clinical and radiographic success in terms of pain, tender on percussion, furcal changes, radiographic healing, resorption Timepoint: 3, 6, 9 and 12 month intervals	—

Countries

India

Contacts

Public ContactDr Jyothsna V Setty

M R Ambedkar Dental College and Hospital, Bangalore

drilasri@yahoo.com9845935042

Outcome results